New Biomarkers in Axial Sypondyloarthropathy; SII and SIRI
In Patients With Axial Spondyloarthropathy; Evaluation of the Relationship Between the Systemic Immune Inflammation Index and the Systemic Inflammatory Response Index With Disease Activity and Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Burak Tayyip DEDE, MD
- Phone Number: 05393426668
- Email: drbrk22.94@gmail.com
Study Locations
-
-
-
Istanbul, Turkey
- Istanbul Training and Resarch Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Group 1:healthy controls working in our hospital,
Group 2: SpA patients diagnosed according to the 2009 Assessment of Spondyloarthritis International Society classification criteria
Description
Inclusion Criteria:
- SpA patients diagnosed according to the 2009 Assessment of Spondyloarthritis International Society classification criteria
- 51 healthy controls working in our hospital,
Exclusion Criteria:
infections, coronary artery disease, kidney and liver dysfunction, cancer diagnosis, surgery in the last three months, diabetes mellitus diagnosis, hypertension and pregnant women
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
group 1
healthy controls
|
Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
|
|
group 2
axial spondyloarthropathy
|
Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of SIRI and SII between Patient and Healthy Control
Time Frame: Baseline
|
SIRI= neutrophil count*monocyte count/lymphocyte count and SII= neutrophil count*platelet count/lymphocyte count.
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation analysis of SIRI and SII with scales and laboratory findings
Time Frame: Baseline
|
SIRI= neutrophil count*monocyte count/lymphocyte count and SII= neutrophil count*platelet count/lymphocyte count.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Burak Tayyip DEDE, MD, Istanbul Training and Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19/08/2022, 2011-KAEK-50: 262
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Axial Spondyloarthritis
-
NCT07339566Not yet recruitingNon-Radiographical Axial Spondyloarthritis | Nr-axial Spondyloarthritis
-
NCT06807853RecruitingAxial Spondyloarthritis | Axial and Peripheral Spondyloarthritis | Axial Spondyloarthopathy | Axial Spondyloarthritis and Ankylosing Spondylitis | Axial Spondyloarthritis (AxSpA) | Axial Spondylarthritis (r-axSpA) | Axial Spondyloarthritis, Non-Radiographic
-
NCT07349329Not yet recruitingAxial Spondyloarthritis, Non-Radiographic
-
NCT03928704CompletedNonradiographic Axial Spondyloarthritis
-
NCT06860750RecruitingA Trial of SHR-1314 Injection in Adult Patients With Active Non-radiographic Axial SpondyloarthritisActive Non-radiographic Axial Spondyloarthritis
-
NCT07582146Not yet recruitingEffectiveness and Safety of Acemetacin in Active Axial Spondyloarthritis: A Real-world Study (ARISE)Axial Spondyloarthritis | Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA) | Axial Spondyloarthritis, Non-Radiographic
-
NCT05622708Active, not recruitingNon-radiographic Axial Spondyloarthritis
-
NCT04732117CompletedNon-radiographic Axial Spondyloarthritis
-
NCT06222671RecruitingAxial Spondyloarthritis
-
NCT03253796Completed
Clinical Trials on lab testing
-
NCT02950142CompletedLiver Diseases | Cardiovascular Diseases | Sexually Transmitted Diseases | Hypertension | Obesity | Diabetes Mellitus | Fatigue | Chronic Kidney Diseases | Thyroid Diseases | Rheumatoid Arthritis
-
NCT03066128Completed
-
NCT00487006CompletedHyperglycemia | Critical Illness
-
NCT05458895Completed
-
NCT04466501CompletedHypertension | Diabetes
-
NCT04796285Active, not recruitingSepsis | Infectious Disease | Lactate Blood Increase | Sepsis Bacterial